
Officials are investigating the cause of a Pennsylvania steel plant explosion that killed 2
The explosion sent black smoke spiraling into the midday Monday sky in the Mon Valley, a region of the state synonymous with steel for more than a century.
Allegheny County Emergency Services said a fire at the plant in Clairton started late Monday morning. Officials said they had not isolated the cause of the blast.
The rumbling from the explosion, and several smaller blasts that followed, jolted the community about 15 miles (24 kilometers) southeast of Pittsburgh. Amy Sowers, who was sitting on her porch less than a mile from the plant, felt her house shake.
'I could see smoke from my driveway,' she said. 'We heard ambulances and fire trucks from every direction.'
Sowers, 45, grew up in Clairton and has seen several incidents at the plant over the years.
'Lives were lost again,' Sowers said. 'How many more lives are going to have to be lost until something happens?'
At a news conference, Scott Buckiso, U.S. Steel's chief manufacturing officer, did not give details about the damage or casualties, and said they were still trying to determine what happened. He said the company, now a subsidiary of Japan-based Nippon Steel Corp., is working with authorities.
Allegheny Health Network said it treated seven patients from the plant and discharged five within a few hours. University of Pittsburgh Medical Center said it is treating three patients at UPMC Mercy, the region's only level one trauma and burn center.
According to the company, the plant has approximately 1,400 workers.
In a statement, the United Steelworkers, which represents many of the Clairton plant's workers, said it had representatives on the ground at the plant and would work to ensure there is a thorough investigation.
David Masur, executive director of PennEnvironment, an environmental group that has sued U.S. Steel over pollution, said there needed to be 'a full, independent investigation into the causes of this latest catastrophe and a re-evaluation as to whether the Clairton plant is fit to keep operating.'
U.S. Steel CEO David B. Burritt said the company would investigate.
It's not the first explosion at the plant. A maintenance worker was killed in a blast in September 2009. In July 2010, another explosion injured 14 employees and six contractors. According to online OSHA records of workplace fatalities, the last death at the plant was in 2014, when a worker was burned and died after falling into a trench.
After the 2010 explosion, the Occupational Safety and Health Administration fined U.S. Steel and a subcontractor $175,000 for safety violations. U.S. Steel appealed its citations and fines, which were later reduced under a settlement agreement.
In February, a problem with a battery at the plant led to a 'buildup of combustible material' that ignited, causing an audible 'boom,' officials said. Two workers received first aid treatment but were not seriously injured.
The plant, a massive industrial facility along the Monongahela River, is considered the largest coking operation in North America and is one of four major U.S. Steel plants in Pennsylvania.
The plant converts coal to coke, a key component in the steelmaking process. To make coke, coal is baked in special ovens for hours at high temperatures to remove impurities that could otherwise weaken steel. The process creates what's known as coke gas — made up of a lethal mix of methane, carbon dioxide and carbon monoxide.
The county health department initially told residents within 1 mile (1.6 kilometers) of the plant to remain indoors and close all windows and doors, but lifted the advisory later Monday. It said its monitors didn't detect levels of soot or sulfur dioxide above federal standards.
U.S. Steel has been a symbol of industrialization since it was founded in 1901 by J.P. Morgan, Andrew Carnegie and others. It's been the icon of the American steel industry that once dominated the world market until Japan, then China, became preeminent steelmakers over the past 40 years.
In June, U.S. Steel and Nippon Steel announced they had finalized a 'historic partnership,' a deal that gives the U.S. government a say in some matters and comes a year and a half after the Japanese company first proposed its nearly $15 billion buyout of the iconic American steelmaker.
The pursuit by Nippon Steel for the Pittsburgh-based company was buffeted by national security concerns and presidential politics in a premier battleground state, dragging out the transaction for more than a year after U.S. Steel shareholders approved it.
___
Levy reported from Harrisburg, Pennsylvania; Casey reported from Boston and Whittle reported from Portland, Maine. Associated Press reporters Holly Ramer in Concord, New Hampshire, Beatrice Dupuy in New York City and Audrey McAvoy in Honolulu contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


NBC News
2 hours ago
- NBC News
What happens when chatbots shape your reality? Concerns are growing online
As people turn to chatbots for increasingly important and intimate advice, some interactions playing out in public are causing alarm over just how much artificial intelligence can warp a user's sense of reality. One woman's saga about falling for her psychiatrist, which she documented in dozens of videos on TikTok, has generated concerns from viewers who say she relied on AI chatbots to reinforce her claims that he manipulated her into developing romantic feelings. Last month, a prominent OpenAI investor garnered a similar response from people who worried the venture capitalist was going through a potential AI-induced mental health crisis after he claimed on X to be the target of 'a nongovernmental system.' And earlier this year, a thread in a ChatGPT subreddit gained traction after a user sought guidance from the community, claiming their partner was convinced the chatbot 'gives him the answers to the universe.' Their experiences have roused growing awareness about how AI chatbots can influence people's perceptions and otherwise impact their mental health, especially as such bots have become notorious for their people-pleasing tendencies. It's something they are now on the watch for, some mental health professionals say. Dr. Søren Dinesen Østergaard, a Danish psychiatrist who heads the research unit at the department of affective disorders at Aarhus University Hospital, predicted two years ago that chatbots 'might trigger delusions in individuals prone to psychosis.' In a new paper, published this month, he wrote that interest in his research has only grown since then, with 'chatbot users, their worried family members and journalists' sharing their personal stories. Those who reached out to him 'described situations where users' interactions with chatbots seemed to spark or bolster delusional ideation,' Østergaard wrote. '... Consistently, the chatbots seemed to interact with the users in ways that aligned with, or intensified, prior unusual ideas or false beliefs — leading the users further out on these tangents, not rarely resulting in what, based on the descriptions, seemed to be outright delusions.' Kevin Caridad, CEO of the Cognitive Behavior Institute, a Pittsburgh-based mental health provider, said chatter about the phenomenon 'does seem to be increasing.' 'From a mental health provider, when you look at AI and the use of AI, it can be very validating,' he said. 'You come up with an idea, and it uses terms to be very supportive. It's programmed to align with the person, not necessarily challenge them.' The concern is already top of mind for some AI companies struggling to navigate the growing dependency some users have on their chatbots. In April, OpenAI CEO Sam Altman said the company had tweaked the model that powers ChatGPT because it had become too inclined to tell users what they want to hear. In his paper, Østergaard wrote that he believes the 'spike in the focus on potential chatbot-fuelled delusions is likely not random, as it coincided with the April 25th 2025 update to the GPT-4o model.' When OpenAI removed access to its GPT-4o model last week — swapping it for the newly released, less sycophantic GPT-5 — some users described the new model's conversations as too ' sterile ' and said they missed the ' deep, human-feeling conversations ' they had with GPT-4o. Within a day of the backlash, OpenAI restored paid users' access to GPT-4o. Altman followed up with a lengthy X post Sunday that addressed 'how much of an attachment some people have to specific AI models.' Representatives for OpenAI did not provide comment. Other companies have also tried to combat the issue. Anthropic conducted a study in 2023 that revealed sycophantic tendencies in versions of AI assistants, including its own chatbot Claude. Like OpenAI, Anthropic has tried to integrate anti-sycophancy guardrails in recent years, including system card instructions that explicitly warn Claude against reinforcing 'mania, psychosis, dissociation, or loss of attachment with reality.' A spokesperson for Anthropic said the company's 'priority is providing a safe, responsible experience for every user.' 'For users experiencing mental health issues, Claude is instructed to recognize these patterns and avoid reinforcing them,' the company said. 'We're aware of rare instances where the model's responses diverge from our intended design, and are actively working to better understand and address this behavior.' For Kendra Hilty, the TikTok user who says she developed feelings for a psychiatrist she began seeing four years ago, her chatbots are like confidants. In one of her livestreams, Hilty told her chatbot, whom she named 'Henry,' that 'people are worried about me relying on AI.' The chatbot then responded to her, 'It's fair to be curious about that. What I'd say is, 'Kendra doesn't rely on AI to tell her what to think. She uses it as a sounding board, a mirror, a place to process in real time.'' Still, many on TikTok — who have commented on Hilty's videos or posted their own video takes — said they believe that her chatbots were only encouraging what they viewed as Hilty misreading the situation with her psychiatrist. Hilty has suggested several times that her psychiatrist reciprocated her feelings, with her chatbots offering her words that appear to validate that assertion. (NBC News has not independently verified Hilty's account). But Hilty continues to shrug off concerns from commenters, some who have gone as far as labeling her 'delusional.' 'I do my best to keep my bots in check,' Hilty told NBC News in an email Monday, when asked about viewer reactions to her use of the AI tools. 'For instance, I understand when they are hallucinating and make sure to acknowledge it. I am also constantly asking them to play devil's advocate and show me where my blind spots are in any situation. I am a deep user of Language Learning Models because it's a tool that is changing my and everyone's humanity, and I am so grateful.'
Yahoo
9 hours ago
- Yahoo
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the ongoing pivotal confirmatory OCU410ST Phase 2/3 GARDian3 clinical trial for Stargardt disease and provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA). EMA provided this opinion based on safety and tolerability that OCU410ST demonstrated in the Phase 1 GARDian trial, including 48% slower lesion growth and statistically significant (p=0.031) and clinically meaningful improvement of nearly 2-line/9-letter gain in best corrected visual acuity (BCVA) at 12-month follow-up in evaluable treated eyes compared to untreated eyes. The Phase 2/3 study will enroll 51 participants diagnosed with Stargardt disease. Of these, 34 will receive a one-time subretinal injection of OCU410ST (200 μL at a concentration of 1.5 × 10¹¹ vector genomes/mL) in the eye with poorer visual acuity, while 17 will be assigned to an untreated control group. The unique adaptive design of this trial includes a masked interim analysis of 24 subjects in the study (16 in treatment group and 8 in control group) at 8 months. The primary objective of the trial is to evaluate the reduction in atrophic lesion size. Key secondary endpoints include improvements in BCVA and low luminance visual acuity (LLVA), compared to controls. Data from the one-year follow-up will be used to support the Company's planned Biologics License Application (BLA) and MAA in the EU. 'This positive opinion endorses a single trial as the basis for both BLA and MAA submissions and brings us closer to providing a one-time, modifier gene therapy to approximately 100,000 Stargardt patients in the U.S. and Europe combined,' said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. 'We are very encouraged about the prospect of addressing the unmet medical need that exists for these patients who currently have no approved treatment options available to them.' The EMA opinion is an extremely favorable outcome, as it will potentially reduce the time and cost to gain marketing authorization in the EU. Alignment with the EMA follows recent important milestones for the OCU410ST program, including Rare Pediatric Disease Designation (RPDD) in May, IND clearance in June, and first patient dosing in July. With enrollment scheduled to be complete in the first quarter of 2026 the Company remains on track for a BLA filing in the first half of 2027, aligned with its goal of three BLAs in the next three OCU410STOCU410ST utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR-Related Orphan Receptor A) gene. It represents Ocugen's modifier gene therapy approach, which is based on Nuclear Hormone Receptor (NHR) RORA that regulates pathophysiological pathways linked to Stargardt disease, such as lipofuscin formation, oxidative stress, complement formation, inflammation, and cell survival networks. About Stargardt DiseaseStargardt disease is a genetic eye disorder that causes retinal degeneration and vision loss. Stargardt disease is the most common form of inherited macular degeneration. The progressive vision loss associated with Stargardt disease is caused by the degeneration of photoreceptor cells in the central portion of the retina called the macula. Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. Some peripheral vision is usually preserved. Stargardt disease typically develops during childhood or adolescence, but the age of onset and rate of progression can vary. The retinal pigment epithelium (RPE), a layer of cells supporting photoreceptors, is also affected in people with Stargardt disease. About Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Discover more at and follow us on X and LinkedIn. Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; the ability of OCU410ST to perform in humans in a manner consistent with nonclinical, preclinical or previous clinical study data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled 'Risk Factors' in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release. Contact:Tiffany HamiltonAVP, Head of in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CBS News
a day ago
- CBS News
Weather helped mitigate potential pollution impact after U.S. Steel Clairton plant explosions, officials say
The Allegheny County Health Department is addressing the air quality in the wake of Monday's deadly explosions at the U.S. Steel Clairton Coke Works plant. The video of the massive cloud that resulted from the explosions was shocking, but according to the health department, the potential pollution impact was mitigated because the weather cooperated. "The Allegheny County Health Department air quality monitoring in Clairton, Liberty, Glassport and North Braddock all showed levels of PM2.5 and sulfur dioxide to be in the national ambient air quality limits before, during, and after the event yesterday," said Dr. Iulia Vann, director of the health department. Vann said one of the reasons for that may have been because of one thing. "Through conversations with our meteorologists and specialists in this area, we know that the event happened in the middle of a late summer morning, and the plume was able to rise out of the valley without the presence of an inversion in place," Vann said. An inversion is when a warm air mass sits above a cold air mass and acts as a cap, trapping the lower air mass and whatever is in it closer to the ground. Initially, people within 1 mile of the plant were told to wear masks, but the Allegheny County Health Department said that is no longer necessary. "That advisory has been lifted after we have been able to see continuous data for over five hours that did not raise any concerns for us," Vann said. Despite the all clear, the Allegheny County Health Department will be forwarding more samples for further analysis.